From prediction and prevention of spontaneous preterm birth to management of acute preterm labor; A dose-level, evidence-based clinical review for cervical length, fetal fibronectin, vaginal progesterone, cerclage, antenatal corticosteroid, magnesium sulfate neuroprotection, and tocolysis.
⚕️ Target audience: This clinical review is intended for physicians and healthcare professionals; It is a summary of current literature and guidelines for educational purposes. Clinical decisions should be made based on patient-specific evaluation and applicable institutional protocols.
Preterm birth is defined as birth occurring between 20 0/7 and 36 6/7 weeks of pregnancy; Preterm labor is characterized by cervical changes (effacement and/or dilation) accompanied by regular uterine contractions. Approximately 1 in 10 newborns in the United States are born preterm, and these infants are responsible for approximately three-quarters of perinatal mortality and more than half of long-term neurological morbidity (ACOG Practice Bulletin No. 234, 2021). Approximately half of spontaneous preterm births follow spontaneous preterm labor, and a quarter follow premature rupture of membranes (PPROM); The remaining one quarter are births planned for maternal or fetal indications (medically indicated).
Clinically relevant subgroups by gestational age are extremely preterm (<28 weeks), very preterm (28 0/7–31 6/7 weeks), moderate preterm (32 0/7–33 6/7 weeks), and late preterm (34 0/7–36 6/7 weeks). Morbidity and mortality increase exponentially as gestational age decreases; Therefore, each full week of pregnancy extension provides a significant benefit in terms of neonatal outcomes, especially between 24–32 weeks.
Spontaneous preterm birth is not a single disease but a heterogeneous syndrome tending towards a common final pathway (premature myometrial activation, cervical insufficiency and decidual-chorionic membrane dissociation). Major pathophysiological pathways include intrauterine infection/inflammation, decidual bleeding (abruption), pathological uterine distension (multiple pregnancy, polyhydramnios), cervical insufficiency, and premature hypothalamic-pituitary-adrenal axis activation due to maternal-fetal stress (ACOG PB 234, 2021).
The strongest predictive risk factor is a history of previous spontaneous preterm birth; The risk of recurrence increases significantly in women with this history. Other important risk factors are short cervical length (on mid-trimester transvaginal ultrasonography), multiple pregnancy, previous cervical surgery (conization, LEEP), uterine anomalies, short interpregnancy interval, low maternal body mass index, smoking, genitourinary infections and socioeconomic disadvantages. However, a significant portion of preterm births occur in women with no known risk factors; This explains the limitations of population-based screening.
Two basic tools stand out in the prediction of spontaneous preterm birth: transvaginal cervical length measurement and fetal fibronectin (fFN).
Short cervix measured on transvaginal ultrasonography in the mid-trimester (usually 16–24 weeks) is a strong and quantifiable marker of risk of spontaneous preterm birth; The risk increases nonlinearly as cervical length decreases (ACOG PB 234, 2021). In singleton pregnancies, a cervical length of ≤25 mm before 24 weeks is widely accepted as the threshold for intervention. In symptomatic (contracting) patients, a cervical length below 30 mm before 34 weeks indicates an increased risk of preterm birth, while a length of ≥30 mm has a high negative predictive value and prevents unnecessary hospitalization (UpToDate, "Preterm labor: Clinical findings", 2025).
fFN is an extracellular matrix protein located at the decidual-chorionic interface; Disruption of this interface leads to the release of fFN into cervicovaginal secretions. A value ≥50 ng/mL in the qualitative test is considered positive in patients between 22 0/7–34 6/7 weeks gestation with intact membranes, cervical dilatation <3 cm, and no significant vaginal bleeding, and is associated with an increased risk of delivery within seven days. The most valuable feature of fFN is its high negative predictive value: a negative result largely excludes birth within seven days (UpToDate, 2025). However, the use of fFN alone, without taking into account cervical length and other factors, does not reduce the rates of hospitalization or preterm birth; Therefore, the current approach is to use fFN in selected symptomatic patients with intermediate cervical length (e.g. 20–29 mm). Coitus (within the previous 24 hours), grossly bloody sample, and digital cervical examination may lead to false positivity.
Vaginal progesterone significantly reduces preterm birth and adverse perinatal outcomes in the presence of a short cervix detected sonographically in the middle trimester of a singleton pregnancy. In a meta-analysis based on individual patient data, vaginal progesterone significantly reduced the risk of preterm birth before 33 weeks (RR 0.62; 95% CI 0.47–0.81), without demonstrable adverse effects on childhood neurodevelopment (Romero et al., AJOG 2018, PMID 29157866). The large EPPPIC meta-analysis of individual patient data also supported that vaginal progesterone in singleton pregnancies reduces preterm birth in women with a short cervix and/or a previous history of preterm birth (EPPPIC, Lancet 2021).
Indications for cerclage are evaluated separately based on history, transvaginal ultrasound and physical examination findings. The following thresholds are for asymptomatic singleton pregnancies; There are differences between authorities.
The evidence and institutional approaches for the combined use of progesterone and cerclage are not the same; The routine combination is not generalized to all patients. Limit of new evidence: benefit in the 2025 IPD meta-analysis was seen in a subgroup with short cervix; The randomized trial comparing cerclage + progesterone with progesterone alone was terminated early due to slow enrollment and showed no significant difference in the primary preterm birth outcome. UpToDate's October 20, 2026 synthesis discusses these data as options in the selected case. These findings do not mean that SMFM #70's recommendation for the 10–25 mm/non-dilatation group has changed to routine cerclage for all pregnant women. The decision is individualized by source name, actual measurement, history, and examination findings.
Suspicious (threatening) preterm labor is one of the most common causes of hospitalization during pregnancy; however, even without tocolytic therapy, approximately 50% of these patients deliver at term (UpToDate, 2025). Therefore, correctly distinguishing true preterm labor is critical both to apply effective interventions in a timely manner and to avoid unnecessary interventions.
Diagnostic evaluation includes documentation of regular contractions, sterile speculum examination (assessment of membrane rupture and cervical dilation, with fFN sampling if needed), transvaginal cervical length measurement, obstetric ultrasonography for fetal presentation and amniotic fluid, and GBS culture if not performed within the preceding five weeks. If cervical dilation is ≥3 cm, the diagnosis is supported and no further testing is needed; when dilation is <3 cm, cervical length (and fFN in selected cases) helps reduce diagnostic uncertainty. Four core interventions are considered in diagnosed pregnancies at <34 weeks: antenatal corticosteroids, short-term tocolysis, GBS prophylaxis when indicated, and magnesium sulfate neuroprotection at <32 weeks, along with maternal transfer if advanced neonatal care is needed.
Antenatal corticosteroids are the most important antenatal treatment available for pregnancies at risk of preterm birth. More than twenty randomized studies have shown that ACS reduces the incidence and severity of respiratory distress syndrome (RDS), reduces neonatal mortality, and reduces rates of intraventricular hemorrhage (IVH) and necrotizing enterocolitis (Cochrane, McGoldrick et al., 2020, CD004454.pub4, PMID 33368142). The current Cochrane update confirms that a single course of ACS reduces the risk of perinatal death, neonatal death and RDS, and possibly reduces the risk of IVH.
ACS should be performed when preterm birth is highly likely to occur within the next 1–7 days; maximum effect occurs 24 hours–7 days after the first dose, with incomplete effect at <24 hours and diminishing after 7 days (UpToDate, "Antenatal corticosteroid therapy", 2026). No clear superiority has been demonstrated between betamethasone and dexamethasone; both undergo limited metabolism by placental 11β-hydroxysteroid dehydrogenase type 2 and reach maximum fetal effect.
| Medication / Condition | Dosage and administration | Note |
|---|---|---|
| Betamethasone | 12 mg IM, 2 doses 24 hours apart | Preferred regimen; each ampoule 3 mg sodium phosphate + 3 mg acetate |
| Dexamethasone | 6 mg IM, 4 doses 12 hours apart | Faster onset, short effect; avoid oral use |
| Standard indication | 24 0/7 – 33 6/7 weeks, high risk of preterm birth within 7 days | ACOG CO 713; May be considered if active neonatal management is planned at 22 0/7–23 6/7 weeks |
| Late preterm (selected) | 34 0/7 – 36 6/7 weeks, high risk singleton pregnancy within 7 days | SMFM/ACOG (ALPS data); Those with diabetes, multiple pregnancy, and previous ACS should be excluded; risk of neonatal hypoglycemia ↑ |
| Repeat (rescue) course | <34 0/7 weeks; >14 days have passed since the previous cycle; A single dose of 12 mg betamethasone is reasonable | ACOG; multiple repeat cycles (>1) are avoided (risk of SGA and placental weight loss) |
The use of ACS in the late preterm period (34 0/7–36 6/7 weeks) is controversial: although the ALPS study showed a reduction in severe respiratory morbidity, there is no survival benefit, the absolute respiratory benefit is lower, and the risk of neonatal hypoglycemia is significantly increased (RR 1.61; 95% CI 1.16–2.12). Due to concerns about long-term neuropsychiatric effects, some experts limit ACS during this window to high-risk, especially planned cesarean candidates, and recommend shared decision-making (UpToDate, 2026). In diabetic pregnant women, ACS can be given when necessary, but secondary hyperglycemia should be closely monitored and treated; The steroid's effect on glucose begins ~12 hours after the first dose and may last up to five days.
Prenatal administration of magnesium sulfate reduces cerebral palsy and the combined risk of cerebral palsy and death in very/extremely preterm neonates born before 32 weeks (ACOG Committee Opinion No. 455, 2010; CO 652 "Magnesium Sulfate Use in Obstetrics", 2016). A current Cochrane systematic review confirms this benefit; report that magnesium sulfate reduces cerebral palsy and the composite outcome of death or cerebral palsy up to two years of age, as well as possibly reducing severe intraventricular hemorrhage (Shepherd, Crowther et al., Cochrane 2024, CD004661.pub4, PMID 38726883). The minimum application time that provides neuroprotection is unknown but is less than 24 hours.
Magnesium provides neuroprotection through N-methyl-D-aspartate (NMDA) receptor blockade and anti-inflammatory effects. A common regimen for neuroprotection is 4 g IV loading ± 1 g/h maintenance (minimal dose approach; ACOG CO 455). MgSO4 is contraindicated in myasthenia gravis and significant myocardial insufficiency/conduction defect; In case of renal dysfunction, the maintenance dose should be reduced or discontinued because magnesium is excreted by the kidney. Monitoring is done clinically (deep tendon reflexes, respiratory rate, urine output); routine serum level is not required (except in neonatal/renal failure). In life-threatening toxicity (cardiac/respiratory suppression), the antidote is calcium gluconate 1 g IV (over 5–10 minutes).
The purpose of tocolysis is not to stop labor; The aim is to delay birth for up to 48 hours in order for ACS to reach its full effect, to ensure maternal transfer to a center that provides an appropriate level of neonatal care when necessary, and to apply magnesium for neuroprotection (UpToDate, "Inhibition of acute preterm labor", 2025). Tocolytics are superior to placebo at 48 hours delay; Maintenance tocolysis is ineffective. Drug selection is based on effectiveness, safety and gestational age.
| Agent | Dose | Preferred GA | Major contraindication / warning |
|---|---|---|---|
| Indomethacin (COX inhibitor) | 50–100 mg loading (oral/rectal), followed by 25 mg orally every 4–6 hours (max. 200 mg/day); ≤72 hours | Only <32 0/7 weeks | >32 0/7 weeks: CONTRAINDICATED (ductus arteriosus constriction, oligohydramnios); also contraindicated with platelet dysfunction, liver/kidney impairment, GI ulcer or aspirin hypersensitivity |
| Nifedipine (calcium channel blocker) | 20–30 mg oral loading followed by 10–20 mg orally every 3–8 hours (max. 180 mg/day); ≤48 hours | <32 weeks (if indomethacin is contraindicated) and 32 0/7–34 0/7 weeks (first line) | Hypotension, preload-dependent cardiac lesion; Synergistic suppression with MgSO4 (rarely serious) |
| Terbutaline (beta-agonist) | 0.25 mg SC every 20–30 minutes (up to 4 doses or until tocolysis is achieved); ≤48–72 hours | Alternative if others are contraindicated | FDA: prolonged (>48–72 hours) use and oral terbutaline not recommended (risk of serious maternal cardiac events/death); heart disease susceptible to tachycardia, uncontrolled hyperthyroidism |
| Atosiban (oxytocin receptor antagonist) | 6.75 mg IV bolus → 300 mcg/min (3 hours) → 100 mcg/min (≤45 hours) | used in Europe | Not FDA approved in the US; No absolute contraindications have been reported |
In the current approach, first-line for <32 0/7 weeks is indomethacin (compatible with concurrent magnesium neuroprotection); If there is a contraindication, nifedipine is preferred. Between ≥32 0/7 and ≤34 0/7 weeks, first-line is nifedipine due to the adverse effects of indomethacin on the ductus arteriosus at this gestational age (UpToDate, 2025). The risk of ductal constriction with indomethacin increases significantly after 31–32 weeks and with use exceeding 48 hours; Therefore, it is not used after 32 0/7 weeks and its duration is limited to 72 hours. Absolute contraindications to tocolysis include intrauterine fetal death, lethal fetal anomaly, impaired fetal status, severe preeclampsia/eclampsia, hemodynamic instability with maternal bleeding, chorioamnionitis, and drug-specific contraindications. Magnesium sulfate is not routinely recommended as a primary tocolytic; However, when given for neuroprotection purposes, it may provide a short-term tocolytic effect.
In patients with preterm labor and no negative GBS culture within the last five weeks, intrapartum antibiotic prophylaxis against early-onset neonatal group B streptococcal (GBS) disease is initiated (ACOG Committee Opinion No. 797, 2020). GBS culture is sent; Prophylaxis is initiated in preterm labor while waiting for the result. Prophylaxis is most effective when started at least 4 hours before birth. The preferred agent is penicillin G: initial dose of 5 million units IV, then 2.5–3 million units IV every 4 hours until birth; Ampicillin 2 g IV initially, followed by 1 g every 4 hours, is an acceptable alternative (UpToDate, “Prevention of early-onset GBS disease,” 2024).
| Status | Agent and dose |
|---|---|
| No allergy (optional) | Penicillin G 5 million U IV, then 2.5–3 million U IV every 4 hours |
| No allergy (alternative) | Ampicillin 2 g IV, then 1 g IV every 4 hours |
| Low risk penicillin allergy (no risk of anaphylaxis) | Cefazolin 2 g IV, then 1 g IV every 8 hours |
| Risk of anaphylaxis + sensitive to clindamycin | Clindamycin 900 mg IV every 8 hours (if sensitivity + inducible resistance negative) |
| Risk of anaphylaxis + clindamycin resistant/unknown | Vancomycin (ACOG: 20 mg/kg IV every 8 hours, single dose max. 2 g) |
Erythromycin is not recommended for prophylaxis due to high GBS resistance rates (~55% in US data); The use of clindamycin depends on susceptibility testing, and if erythromycin resistance is present, D-zone testing for inducible clindamycin resistance should be performed. Emergency caesarean section should not be delayed to provide ≥4 hours of prophylaxis.
In cases where preterm birth is expected, especially in cases of <32 weeks or expected low birth weight, antepartum (in utero) maternal transfer to a tertiary center with an appropriately equipped neonatal intensive care unit is associated with better outcomes than postnatal neonatal transfer and is one of the primary uses of the time saved by tocolysis.
ACOG Practice Bulletin No. 234 (2021) and Committee Opinion No. 713 (2017) remains in effect; No new ACOG guidance has been issued in the 2024–2026 period that completely replaces these documents. However, individual patient data (IPD) meta-analyses and long-term follow-up studies of the last two years have concretely updated the following points in short cervix management and late preterm steroid use.
Romero et al. updated their individual patient data meta-analysis for singleton pregnancy with a midtrimester short cervix (cervical length ≤25 mm). The study by Çetingöz et al., which had been included in the pooled dataset of the earlier version, was excluded after being retracted by the journal (retraction, 2024); nevertheless, the findings held. In the updated pool (4 trials, 966 patients), vaginal progesterone significantly reduced preterm birth before 33 weeks' gestation: RR 0.63 (95% CI 0.48–0.82), high-certainty evidence; low birth weight, neonatal morbidity and mortality, and neonatal intensive care unit admission also declined (Romero et al., Am J Obstet Gynecol 2025; PMID 40089095). This update supersedes the 2018 analysis (PMID 29157866) cited in the current guideline to support the singleton short-cervix recommendation—citations should be updated to the 2025 analysis because the earlier meta-analysis included the retracted trial. The clinical indication remains unchanged: vaginal progesterone is recommended for singleton pregnancies with cervical length ≤25 mm regardless of prior preterm birth history.
The same group published a separate updated IPD analysis for twin pregnancy + short cervix (≤25 mm); signaled that vaginal progesterone reduces preterm birth and adverse perinatal outcomes in this subgroup (Romero et al., Ultrasound Obstet Gynecol 2025; PMID 40356495). This data for twin + short cervix constitutes a new addition, as the current guideline addresses progesterone only in the context of a singleton pregnancy.
Limit of new evidence: Benefit in the 2025 IPD meta-analysis was seen in a subgroup with short cervix; The randomized trial comparing cerclage + progesterone with progesterone alone was terminated early due to slow enrollment and showed no significant difference in the primary preterm birth outcome. UpToDate's October 20, 2026 synthesis discusses these data as options in the selected case. These findings do not mean that SMFM #70's recommendation for the 10–25 mm/non-dilatation group has changed to routine cerclage for all pregnant women. The decision is individualized by source name, actual measurement, history, and examination findings. The above authority-specific thresholds should be taken as basis (Berghella et al., 2025; Boelig et al., 2025; UpToDate v108).
Hologic has discontinued sales of the Rapid fFN (10Q cassette) and PeriLynx analyzers globally as of September 30, 2024. Systems that routinely recommend fFN (e.g. NICE/NHS) are shifting their approach to cervical length measurement and history-based algorithms (such as QUiPP) (RANZCOG statement, 2024; context PMC11879916, 2025). The phrase “qualitative fFN manufacturer (USA) has discontinued production” in the current guidance should be updated to be dated and globally comprehensive (Hologic, September 2024).
ALPS study children followed ≥6 years of age (949 children, MFMU Network); There was no difference between betamethasone and placebo in the primary outcome, General Conceptual Ability score <85 (17.1% vs 18.5%), and no difference was detected in secondary neurodevelopmental outcomes (Gyamfi-Bannerman et al., JAMA 2024; PMC11044009). These data balance the current guideline's emphasis on "long-term neuropsychiatric concerns": the short-term risk of neonatal hypoglycemia is real, but neurodevelopmental outcomes at age 6 are reassuring. A recent systematic review-meta-analysis (6 RCTs) from 2025 showed that at 34–36 weeks, steroids did not reduce RDS, but significantly reduced the need for surfactant (RR 0.61) and the need for CPAP for ≥2 hours (RR 0.78); There was no difference in NICU admission, hypoglycemia, and neonatal mortality (Zullo et al., Am J Obstet Gynecol MFM 2025; PMID 40418984). Late preterm steroids in diabetic pregnancies were not associated with increased neonatal hypoglycemia in the new cohort data, but did not improve composite respiratory morbidity (Haizler-Cohen et al., Am J Perinatol 2025; PMID 40456285)—with the caveat that benefit in diabetics remains unclear in this window.
WHO's 2022 current recommendation recommends using antenatal steroids only if gestational age can be determined accurately, birth is imminent, there is no maternal infection, and adequate obstetric/newborn care is available; The ACTION-I trial in low-resource settings reduced neonatal mortality without increased harm (Vogel et al., Lancet Glob Health 2022; PMC9681658). The multi-country ACTION-III randomized trial, aiming to resolve global uncertainty in the late preterm window, is ongoing (estimated completion December 2026); Until this is concluded, the difference in emphasis between UpToDate/ACOG-SMFM and WHO in late preterm steroid indication remains. The current evidence base for tocolysis is the Cochrane network meta-analysis (122 studies, 13,697 women) comparing six tocolytic classes: all classes were superior to placebo at 48 hours and 7 days delay; calcium channel blockers stood out as the agent with the lowest side effect/treatment discontinuation rate, and the effect on neonatal mortality remained unclear (Wilson et al., Cochrane Database Syst Rev 2022; PMID 35947046).
The FDA formally withdrew its approval of intramuscular 17-hydroxyprogesterone caproate (Makena) on April 5, 2023, following a negative result from the PROLONG study; SMFM/ACOG no longer recommends this agent for the primary prevention of recurrent preterm labor (SMFM, Am J Obstet Gynecol 2023). Since the molecule can still be prescribed in Türkiye, it would be clinically appropriate to add a short cautionary note to the current guideline.
What has changed in practice: Vaginal progesterone recommendation for singleton short cervix reinforced with current IPD (RR 0.63); In a singleton pregnancy without a history, UpToDate v108 states that cerclage can be offered in selected cases for CL 11–<21 mm before 24 weeks, while SMFM #70 is against cerclage in the range of 10–25 mm in the absence of dilatation (GRADE 1B); The fFN test has been discontinued globally; The 6-year neurodevelopment data of late preterm steroids were reassuring.
Last updated: . Guide numbers and publication years have been verified against current catalogues.